Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 14 2025
0mins
Should l Buy ?
Source: Globenewswire
Appointment of New CFO: Inhibikase Therapeutics has appointed David McIntyre as Chief Financial Officer, effective April 14, 2025, bringing over two decades of experience in the life sciences sector and a strong background in financial strategy and corporate governance.
Company Overview: Inhibikase Therapeutics is focused on developing small molecule kinase inhibitor therapeutics for pulmonary arterial hypertension (PAH), with its lead product IkT-001 aimed at treating this condition.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
